secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-07-06T23:59:59+00:00
Accession:  0001551152-23-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie lowers 2023 adjusted EPS guidance to $10.57-$10.97 on $280M Q2 IPR&D charge
--------------------------------------------------------------------------------

- Q2 2023 includes $280M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.15.
- Full-year 2023 adjusted diluted EPS guidance reduced to $10.57-$10.97 from $10.72-$11.12.
- Q2 2023 adjusted diluted EPS guidance now $2.75-$2.85, down from $2.90-$3.00 prior.
- Company does not forecast further IPR&D expense beyond Q2 due to uncertainty of timing.
- Charge stems from collaborations, licensing agreements, and other asset acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000026/0001551152-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000026/abbv-20230706.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer